The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Cost-Effectiveness of HIV Treatment in Resource-Poor Settings — The Case of Côte d'Ivoire
Abstract
BACKGROUND: As antiretroviral therapy is increasingly used in settings with limited resources, key questions about the timing of treatment and use of diagnostic tests to guide clinical decisions must be addressed. METHODS: We assessed the cost-effectiveness of treatment strategies for a cohort of adults in Côte d'Ivoire who were infected with the human immunodeficiency virus (HIV) (mean age, 33 years; CD4 cell count, 331 per cubic millimeter; HIV RNA level, 5.3 log copies per milliliter). Using a computer-based simulation model that incorporates the CD4 cell count and HIV RNA level as predictors of disease progression, we compared the long-term clinical and economic outcomes associated with no treatment, trimethoprim-sulfamethoxazole prophylaxis alone, antiretroviral therapy alone, and prophylaxis with antiretroviral therapy. RESULTS: Undiscounted gains in life expectancy ranged from 10.7 months with antiretroviral therapy and prophylaxis initiated on the basis of clinical criteria to 45.9 months with antiretroviral therapy and prophylaxis initiated on the basis of CD4 testing and clinical criteria, as compared with trimethoprim-sulfamethoxazole prophylaxis alone. The incremental cost per year of life gained was 240 dollars (in 2002 U.S. dollars) for prophylaxis alone, 620 dollars for antiretroviral therapy and prophylaxis without CD4 testing, and 1,180 dollars for antiretroviral therapy and prophylaxis with CD4 testing, each compared with the next least expensive strategy. None of the strategies that used antiretroviral therapy alone were as cost-effective as those that also used trimethoprim-sulfamethoxazole prophylaxis. Life expectancy was increased by 30% with use of a second line of antiretroviral therapy after failure of the first-line regimen. CONCLUSIONS: A strategy of trimethoprim-sulfamethoxazole prophylaxis and antiretroviral therapy, with the use of clinical criteria alone or in combination with CD4 testing to guide the timing of treatment, is an economically attractive health investment in settings with limited resources.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection
Mellors, J. W., Munoz, A., Giorgi, J. V., Margolick, J. B., Tassoni, C. J., Gupta, P., Kingsley, L. A., Todd, J. A., Saah, A. J., Detels, R., et al. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-12-199706150-00003 · Cited by 2,067
Lucas, G. M., Chaisson, R. E., & Moore, R. D. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-2-199907200-00002 · Cited by 843
Cost-Effectiveness of Cervical-Cancer Screening in Five Developing Countries
Goldie, S. J., Gaffikin, L., Goldhaber-Fiebert, J. D., Gordillo-Tobar, A., Levin, C., Mahé, C., & Wright, T. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa044278 · Cited by 671
Self-citationMurray, C. J., Lauer, J. A., Hutubessy, R. C., Niessen, L., Tomijima, N., Rodgers, A., Lawes, C. M., & Evans, D. B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12655-4 · Cited by 599
Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa
Coetzee, D., Hildebrand, K., Boulle, A., Maartens, G., Louis, F., Labatala, V., Reuter, H., Ntwana, N., & Goemaere, E. (2004) · AIDS · doi:10.1097/00002030-200404090-00006 · Cited by 584
Community-based approaches to HIV treatment in resource-poor settings
Farmer, P., Léandre, F., Mukherjee, J. S., Claude, M. S., Nevil, P., Smith-Fawzi, M. C., Koenig, S. P., Castro, A., Becerra, M. C., Sachs, J., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05550-7 · Cited by 516
The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
Freedberg, K. A., Losina, E., Weinstein, M. C., Paltiel, A. D., Cohen, C. J., Seage, G. R., Craven, D. E., Zhang, H., Kimmel, A. D., & Goldie, S. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441108 · Cited by 508
Self-citationPalella, F. J., Deloria-Knoll, M., Chmiel, J. S., Moorman, A. C., Wood, K. C., Greenberg, A. E., Holmberg, S. D., & and the HIV Outpatient Study (HOPS) Investigators* (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-8-200304150-00007 · Cited by 443
Macroeconomics and Health: Investing in Health for Economic Development
Ivinson, A. J. (2002) · Nature Medicine · doi:10.1038/nm0602-551b · Cited by 436
Cited by
Murray, C. J. L., Ortblad, K. F., Guinovart, C., Lim, S. S., Wolock, T. M., Roberts, D. A., Dansereau, E. A., Graetz, N., Barber, R. M., Brown, J. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60844-8 · Cited by 975
Eddy, D. M., Hollingworth, W., Caro, J. J., Tsevat, J., McDonald, K. M., & Wong, J. B. (2012) · Medical Decision Making · doi:10.1177/0272989x12454579 · Cited by 799
Saag, M. S., Benson, C. A., Gandhi, R. T., Hoy, J. F., Landovitz, R. J., Mugavero, M. J., Sax, P. E., Smith, D. M., Thompson, M. A., Buchbinder, S. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.8431 · Cited by 698
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa
Lawn, S. D., Harries, A. D., Anglaret, X., Myer, L., & Wood, R. (2008) · AIDS · doi:10.1097/qad.0b013e32830007cd · Cited by 639
Self-citationIncreases in Adult Life Expectancy in Rural South Africa: Valuing the Scale-Up of HIV Treatment
Bor, J., Herbst, A. J., Newell, M.-L., & Bärnighausen, T. (2013) · Science · doi:10.1126/science.1230413 · Cited by 578
Eddy, D. M., Hollingworth, W., Caro, J. J., Tsevat, J., McDonald, K. M., & Wong, J. B. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.012 · Cited by 466
Estimating the Lost Benefits of Antiretroviral Drug Use in South Africa
Chigwedere, P., Seage, G. R., Gruskin, S., Lee, T.-H., & Essex, M. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31818a6cd5 · Cited by 413
HIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving Concepts
B. Nachega, J., C. Marconi, V., U. van Zyl, G., M. Gardner, E., Preiser, W., Y. Hong, S., J. Mills, E., & Gross, R. (2011) · Infectious Disorders - Drug Targets · doi:10.2174/187152611795589663 · Cited by 271
Zwarenstein, M., Fairall, L. R., Lombard, C., Mayers, P., Bheekie, A., English, R. G., Lewin, S., Bachmann, M. O., & Bateman, E. (2011) · BMJ · doi:10.1136/bmj.d2022 · Cited by 77
Metadata
- Authors
- Goldie, S. J., Yazdanpanah, Y., Losina, E., Weinstein, M. C., Anglaret, X., Walensky, R. P., Hsu, H. E., Kimmel, A., Holmes, C., Kaplan, J. E., & Freedberg, K. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-14
- Volume
- 355
- Issue
- 11
- Pages
- 1141-1153
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2108259145
- Cited by
- 272
- References
- 34
- FWCI
- 15.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.